Suchith Shetty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suchith Shetty has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Aaqib Habib Malik
Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA
9 shared publications - Ramzi El Accaoui
University Of Iowa Hospitals & Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA
6 shared publications Wilbert S Aronow
Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
4 shared publicationsAlexandros Briasoulis
Department of Cardiology, University of Iowa Health Care, Carver College of Medicine, Iowa City, Iowa, USA
3 shared publicationsSrikanth Yandrapalli
Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, USA
3 shared publicationsWilbert S. Aronow
Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
3 shared publications
Latest Publications
- 1 May 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 331, 158-163
Characteristics, trends, outcomes, and costs of stimulant-related acute heart failure hospitalizations in the United States
- 1 May 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 331, 158-163
Characteristics, trends, outcomes, and costs of stimulant-related acute heart failure hospitalizations in the United States
- 1 December 2020
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 27 (19) , 2113-2115
Renin–angiotensin blockade after aortic valve replacement: A review based on current literature
- 1 December 2020
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 27 (19) , 2113-2115
Renin–angiotensin blockade after aortic valve replacement: A review based on current literature
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 76-80
Impact of acute kidney injury on in-hospital outcomes among patients hospitalized with acute heart failure – A propensity-score matched analysis
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 76-80
Impact of acute kidney injury on in-hospital outcomes among patients hospitalized with acute heart failure – A propensity-score matched analysis
- 1 June 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (12) , 1863-1869
Outcomes of Thoracentesis for Acute Heart Failure in Hospitals
- 1 June 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (12) , 1863-1869
Outcomes of Thoracentesis for Acute Heart Failure in Hospitals
- 28 May 2020
- Published by Springer Nature in Heart Failure Reviews
- Vol. 27 (1) , 263-270
Impact of right ventricular impairment on morbidity and mortality in takotsubo syndrome—a meta-analysis of observational trials
The impact of right ventricular impairment (RVI) on the morbidity and mortality of patients with Takotsubo syndrome (TTS) is well-debated. We conducted a meta-analysis to evaluate the mortality and morbidity risk associated with RVI compared with those without RVI in patients with TTS. A comprehensive search was performed in PubMed and Embase from inception to April 19, 2019. Our primary outcome of interest was in-hospital and long-term mortality. Other outcomes of interest were acute heart failure, left ventricular systolic function, tricuspid and mitral regurgitation, and length of hospital stay (LOS). We are reporting our outcomes as a cumulative odds ratio (OR). After an initial search, 10 studies with 1210 subjects were included in the quantitative analysis. Mean follow-up was 31 months. The odds of in-hospital and long-term mortality in TTS patients with and without RVI were not significantly different (p = 0.13 and 0.40). In TTS patients without RVI, the odds of acute heart failure, and mitral and tricuspid regurgitation were significantly lower at an OR of 0.26 (p < 0.0001), 0.40 (p = 0.0001), and 0.52 (p = 0.02) respectively. TTS patients with RVI had significantly lower mean LVEF (34% vs 41%, p = 0.03) and numerically higher mean LOS (9.5 days vs 7.6 days, p = 0.52) compared with those without RVI. The presence of RVI represents a severe form of TTS disease spectrum, characterized by severely reduced LVEF, higher incidence of MR and presence of TR. Although there was a trend toward increased in-hospital and long-term mortality, RVI in TTS does not portend worse survival.
- 28 May 2020
- Published by Springer Nature in Heart Failure Reviews
- Vol. 27 (1) , 263-270
Impact of right ventricular impairment on morbidity and mortality in takotsubo syndrome—a meta-analysis of observational trials
The impact of right ventricular impairment (RVI) on the morbidity and mortality of patients with Takotsubo syndrome (TTS) is well-debated. We conducted a meta-analysis to evaluate the mortality and morbidity risk associated with RVI compared with those without RVI in patients with TTS. A comprehensive search was performed in PubMed and Embase from inception to April 19, 2019. Our primary outcome of interest was in-hospital and long-term mortality. Other outcomes of interest were acute heart failure, left ventricular systolic function, tricuspid and mitral regurgitation, and length of hospital stay (LOS). We are reporting our outcomes as a cumulative odds ratio (OR). After an initial search, 10 studies with 1210 subjects were included in the quantitative analysis. Mean follow-up was 31 months. The odds of in-hospital and long-term mortality in TTS patients with and without RVI were not significantly different (p = 0.13 and 0.40). In TTS patients without RVI, the odds of acute heart failure, and mitral and tricuspid regurgitation were significantly lower at an OR of 0.26 (p < 0.0001), 0.40 (p = 0.0001), and 0.52 (p = 0.02) respectively. TTS patients with RVI had significantly lower mean LVEF (34% vs 41%, p = 0.03) and numerically higher mean LOS (9.5 days vs 7.6 days, p = 0.52) compared with those without RVI. The presence of RVI represents a severe form of TTS disease spectrum, characterized by severely reduced LVEF, higher incidence of MR and presence of TR. Although there was a trend toward increased in-hospital and long-term mortality, RVI in TTS does not portend worse survival.
- 23 April 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 16 (5) , 433-438
Obstructive Bioprosthetic Mitral Valve Thrombosis
Bioprosthetic valve thrombosis (BPVT) is not uncommon but can be under diagnosed due to the lack of awareness and technical limitations of echocardiography. When suspecting BPVT, it is imperative t...
- 23 April 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 16 (5) , 433-438
Obstructive Bioprosthetic Mitral Valve Thrombosis
Bioprosthetic valve thrombosis (BPVT) is not uncommon but can be under diagnosed due to the lack of awareness and technical limitations of echocardiography. When suspecting BPVT, it is imperative t...
- 1 April 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (7) , 1083-1087
Trends and Outcomes With Transcatheter Versus Surgical Mitral Valve Repair in Patients ≥80 Years of Age
- 1 April 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (7) , 1083-1087
Trends and Outcomes With Transcatheter Versus Surgical Mitral Valve Repair in Patients ≥80 Years of Age
- 1 March 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (6) , 907-915
Meta-Analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients With Hypertension
- 1 March 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (6) , 907-915
Meta-Analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients With Hypertension
- 27 January 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (3) , 361-367
Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis
Aims: This study sought to determine the impact of weight and body mass index (BMI) on the safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in patients with non-valvular atrial fibrillation. Methods and results: A systematic literature search was employed in PubMed, Embase, and Cochrane clinical trials with no language or date restrictions. Randomized trials or their substudies were assessed for relevant outcome data for efficacy that included stroke or systemic embolization (SSE), and safety including major bleeding and all-cause mortality. Binary outcome data and odds ratios from the relevant articles were used to calculate the pooled relative risk. For SSE, the data from the four Phase III trials showed that DOACs are better or similarly effective with low BMI 0.73 (0.56–0.97), normal BMI 0.72 (0.58–0.91), overweight 0.87 (0.76–0.99), and obese 0.87 (0.76–1.00). The risk of major bleeding was also better or similar with DOACs in all BMI subgroups with low BMI 0.62 (0.37–1.05), normal BMI 0.72 (0.58–0.90), overweight 0.83 (0.71–0.96), and obese 0.91 (0.81–1.03). There was no impact on mortality in all the subgroups. In a meta-regression analysis, the effect size advantage of DOACs compared with warfarin in terms of safety and efficacy gradually attenuated with increasing weight. Conclusion: Our findings suggest that a weight-based dosage adjustment may be necessary to achieve optimal benefits of DOACs for thromboembolic prevention in these patients with non-valvular atrial fibrillation. Further dedicated trials are needed to confirm these findings. PROSPERO 2019 CRD42019140693. Available from: https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42019140693.
- 27 January 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (3) , 361-367
Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis
Aims: This study sought to determine the impact of weight and body mass index (BMI) on the safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in patients with non-valvular atrial fibrillation. Methods and results: A systematic literature search was employed in PubMed, Embase, and Cochrane clinical trials with no language or date restrictions. Randomized trials or their substudies were assessed for relevant outcome data for efficacy that included stroke or systemic embolization (SSE), and safety including major bleeding and all-cause mortality. Binary outcome data and odds ratios from the relevant articles were used to calculate the pooled relative risk. For SSE, the data from the four Phase III trials showed that DOACs are better or similarly effective with low BMI 0.73 (0.56–0.97), normal BMI 0.72 (0.58–0.91), overweight 0.87 (0.76–0.99), and obese 0.87 (0.76–1.00). The risk of major bleeding was also better or similar with DOACs in all BMI subgroups with low BMI 0.62 (0.37–1.05), normal BMI 0.72 (0.58–0.90), overweight 0.83 (0.71–0.96), and obese 0.91 (0.81–1.03). There was no impact on mortality in all the subgroups. In a meta-regression analysis, the effect size advantage of DOACs compared with warfarin in terms of safety and efficacy gradually attenuated with increasing weight. Conclusion: Our findings suggest that a weight-based dosage adjustment may be necessary to achieve optimal benefits of DOACs for thromboembolic prevention in these patients with non-valvular atrial fibrillation. Further dedicated trials are needed to confirm these findings. PROSPERO 2019 CRD42019140693. Available from: https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42019140693.
- 1 November 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 124 (9) , 1488-1489
Meta-Analysis for the Use of Renin-Angiotensin Inhibitors in Post-TAVR Patients
- 1 November 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 124 (9) , 1488-1489
Meta-Analysis for the Use of Renin-Angiotensin Inhibitors in Post-TAVR Patients